about
ABC transporter ABCA3 is expressed in acute myeloid leukemia blast cells and participates in vesicular transportIdentification of a new gene regulatory circuit involving B cell receptor activated signaling using a combined analysis of experimental, clinical and global gene expression dataNew insights into the biology and origin of mature aggressive B-cell lymphomas by combined epigenomic, genomic, and transcriptional profiling.Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial.A comprehensive microarray-based DNA methylation study of 367 hematological neoplasmsAlterations of microRNA and microRNA-regulated messenger RNA expression in germinal center B-cell lymphomas determined by integrative sequencing analysis.Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphomaDNA methylome analysis in Burkitt and follicular lymphomas identifies differentially methylated regions linked to somatic mutation and transcriptional control.Loss of p73 promotes dissemination of Myc-induced B cell lymphomas in miceDetection of genomic aberrations in molecularly defined Burkitt's lymphoma by array-based, high resolution, single nucleotide polymorphism analysis.Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing.Classical Hodgkin lymphoma is characterized by recurrent copy number gains of the short arm of chromosome 2.CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.Genetic polymorphisms in the amino acid transporters LAT1 and LAT2 in relation to the pharmacokinetics and side effects of melphalan.Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma.A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma.Exosomal evasion of humoral immunotherapy in aggressive B-cell lymphoma modulated by ATP-binding cassette transporter A3.The PCBP1 gene encoding poly(rC) binding protein I is recurrently mutated in Burkitt lymphoma.Secondary leukaemia after cure for locally advanced NSCLC: alkylating type secondary leukaemia after induction therapy with docetaxel and carboplatin for NSCLC IIIB.MINCR is a MYC-induced lncRNA able to modulate MYC's transcriptional network in Burkitt lymphoma cellsInterleukin-10 gene polymorphisms are associated with freedom from treatment failure for patients with Hodgkin lymphomaValidation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control group.Partial Response to First-Line Crizotinib in an Elderly Male Patient with ROS1 Translocation-Positive Lung Cancer.Yttrium 90 ibritumomab tiuxetan (Zevalin): a new bullet in the fight against malignant lymphoma?B-cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice.SOCS1 mutation subtypes predict divergent outcomes in diffuse large B-Cell lymphoma (DLBCL) patients.USP9X stabilizes XIAP to regulate mitotic cell death and chemoresistance in aggressive B-cell lymphoma.Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma - analyses of cases from two prospective randomized clinical trialsSignificant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DTherapeutic options in relapsed or refractory peripheral T-cell lymphoma.Aberrant lymphocyte enhancer-binding factor 1 expression is characteristic for sporadic Burkitt's lymphoma.Autotransplant with and without induction chemotherapy in older multiple myeloma patients: long-term outcome of a randomized trial.Populational equilibrium through exosome-mediated Wnt signaling in tumor progression of diffuse large B-cell lymphoma.Advanced patient age at diagnosis of diffuse large B-cell lymphoma is associated with molecular characteristics including ABC-subtype and high expression of MYC.Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial.Recurrent deletions of the TNFSF7 and TNFSF9 genes in 19p13.3 in diffuse large B-cell and Burkitt lymphomas.
P50
Q24312681-AF1BB7AF-9747-4428-9E1F-A6D5AA334190Q31095260-085BD3C0-72CA-440D-8BD4-3F7A0228F84AQ33392210-11A9E83F-1CA3-47FA-8010-2C98137F9434Q33430165-B386C4CC-B89F-4F1B-BE3B-C7E631A7615CQ33502760-E2AD13C6-D933-4809-A1F8-E4F13A6ED681Q33573515-0934EFCB-CDAD-4C45-824D-374A14654B96Q33599174-B5E71456-50C6-4313-8522-F9B36B37BB67Q33727517-A1312F8C-CDE8-46B3-9D19-ECE2E368AA46Q33882866-7EF70D28-F6E4-42D5-8666-4AAF077D6E03Q34371069-8A3282E3-E75D-4B71-9A34-8C6FD6289444Q34473466-F2D0A6DB-25E7-472C-BCF0-5F0BB7A34FE9Q34520814-C122BD5B-676F-4105-B95D-CF268C9BA16DQ34566901-C435DF8D-C895-432F-9555-198B40784334Q34611141-C14E43FA-95B6-4029-B972-87D7BB1321C8Q34623144-8DC115D2-4970-4B48-AD78-1A20F1EA68A7Q34635868-54FCB4F5-0CDF-41B2-9A5D-52702089E46EQ34742742-5623FED0-BFDF-4C72-82F9-13B363BB78A1Q35030096-C4A4746A-C54E-4E11-8613-E97E183DD32DQ35084573-D03E41CF-BF76-4E38-A855-1A07D9709E2FQ35216949-122D8A5D-FB3C-40D0-B9D3-285D5C6E410FQ35691157-8FDF2587-D17E-40D4-A87A-81C5FB3E274CQ35745806-239FC1EF-8C4B-4C40-8445-47679FB574F3Q36103110-DF467982-0921-4BB0-B924-481D311697BBQ36565665-D8B33F14-2C71-4F71-8503-EA98F6745F77Q36715932-CCAD58B8-D801-4876-8DEA-5D72A67CC72DQ36766252-9EB81635-4C6E-4C90-8B12-619AFE7327CBQ36948467-66527077-AFDA-483E-A6E5-96A370B7C48BQ36965870-8FA1D3F7-08C0-4FAB-B687-9BEB33C213A9Q36984836-203D21B3-DCCD-46E9-9F3E-F06695455BC0Q37141364-7B8E7B0A-1E6A-41DF-B02B-276F952F17E4Q37406798-D5BBEED7-289F-4404-B1A9-A6EDB6847C04Q37473480-060EB43E-3F89-4EF3-9DAD-FD30A17D93DAQ38246983-6FD85274-D987-4958-9FED-C9B49F307B04Q38318011-D8449E32-B9AE-4A8C-9A79-D09ED1C184FCQ38385465-50C61691-2141-42AA-ACEA-57D3568BD55AQ38399917-516273F5-578F-4E7C-81DD-B93035786DAFQ38609747-B6312306-5F72-42B8-993F-AD471A5782D9Q38681761-32600608-F3B6-4F9F-964A-D73D9CBA422FQ38857091-951D24F7-6F52-417C-88A8-FBE8C4A1BEBDQ39418718-CE302D3F-61D5-4293-92D7-554CCD525278
P50
description
onderzoeker
@nl
name
Lorenz Trümper
@ast
Lorenz Trümper
@en
Lorenz Trümper
@sl
type
label
Lorenz Trümper
@ast
Lorenz Trümper
@en
Lorenz Trümper
@sl
prefLabel
Lorenz Trümper
@ast
Lorenz Trümper
@en
Lorenz Trümper
@sl